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Selective Serotonin Reuptake Inhibitors in Pediatric
Depression: Is the Balance Between Benefits and
Risks Favorable?
Christopher J. Kratochvil, M.D.,1 Benedetto Vitiello, M.D.,2 John Walkup, M.D.,3
Graham Emslie, M.D.,4 Bruce D. Waslick, M.D.,5 Elizabeth B. Weller, M.D.,6
William J. Burke, M.D.,1 and John S. March, M.D.7
ABSTRACT
Recent controversies surrounding the use of selective serotonin reuptake inhibitors (SSRIs)
have highlighted the need to reassess potential benefits, as well as potential risks of this class of
medications in the treatment of pediatric depression. The recent availability of data from meta-
analyses of published and unpublished antidepressant trials, epidemiological studies, and the
Treatment for Adolescents with Depression Study (TADS) has facilitated a reanalysis of this
risk/benefit relationship. Despite reviewing similar data, various regulatory agencies have ar-
rived at rather disparate conclusions regarding the data, resulting in continued controversy. Al-
though all groups appear to agree that careful assessment, education regarding risks, and closer
monitoring are essential for SSRIs, only the U.S. Food and Drug Administration (FDA) and the
U.K. Medicine and Health Care Products Regulatory Agency maintain that an acceptable
risk/benefit relationship exists for fluoxetine. The European Medicines Agency concluded that
the SSRIs should not be used in the treatment of depression in children and adolescents.  The
authors of this review have taken into consideration many of these same data and offer a critical
discussion of the pros and cons of SSRIs in pediatric depression. The authors have concluded
that SSRIs—in particular, fluoxetine—do have a role in the treatment of pediatric depression.
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INTRODUCTION
THE USE OF THE SELECTIVE serotonin reuptakeinhibitors (SSRIs) has grown significantly
in the treatment of pediatric major depressive
disorder (MDD), owing, in part, to efficacy data
in adults, ease of dosing, and perception of good
tolerability and safety in overdose. However,
concerns have arisen intermittently over the
past decade regarding the safety of the SSRIs
in the treatment of MDD. Whereas in adults
the well-documented efficacy of SSRIs ensures
a favorable risk/benefit balance, the paucity of
information in the pediatric population has
made it difficult for clinicians and regulators
to reach the same conclusion in youths. The
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recent availability of meta-analyses completed
by regulatory agencies of published and unpub-
lished industry-sponsored trials, epidemiolog-
ical studies of youth suicide and medication
use, and the Treatment for Adolescents with
Depression Study (TADS) (TADS Team 2004)
have expanded our knowledge-base regarding
the efficacy and safety of SSRIs in young patients.
Based on currently available data, we provide
in this paper a critical discussion of potential
risks and benefits of SSRIs in the treatment of
children and adolescents with depression.
Background and context
Fluoxetine, the first SSRI approved in the
United States for the treatment of MDD, was
made commercially available in 1987. As early
as 1991, the U.S. Food and Drug Administra-
tion (FDA) held a public meeting to address
concerns that fluoxetine was potentially con-
tributing to suicidal behaviors in adults. An
analysis of data pooled from 17 double-blind
clinical trials was presented by fluoxetine’s
manufacturer, Eli Lilly & Co. (Indianapolis,
IN). This analysis showed a greater decline in
symptoms of suicidality endorsed on the
Hamilton Depression Scale by adult patients
taking fluoxetine than those taking placebo
(Beasley et al. 1991). Subsequently, reviews of
clinical trials submitted to the FDA involving
nine antidepressants and 48,000 subjects (77 of
whom completed suicide) did not find a statisti-
cally significant difference in the risk for suicide
or suicide attempt between SSRIs and placebo,
or between SSRIs and other types of antidepres-
sants (Khan et al. 2003; Khan et al. 2000).
The early pediatric literature on the treatment
of MDD with SSRIs was primarily limited to
case reports and small, open-label trials. It
wasn’t until 1997 that the first randomized,
double-blind, placebo-controlled trial showing
the efficacy of fluoxetine in children and ado-
lescents (age, 7–18 years) with MDD was pub-
lished (Emslie et al. 1997). In this National
Institute of Mental Health (NIMH)-funded
study, 56% of the subjects in the fluoxetine
group had improved at the end of the 8-week
trial compared with 33% in the placebo group
(p < 0.05). In 1998, based, in part, on that trial,
the practice guidelines published by the Amer-
ican Academy of Child and Adolescent Psychi-
atry (AACAP) recommended SSRIs as initial
therapy in the acute phase of MDD (Birmaher
et al. 1998). This was followed by an increase
in prescribing SSRIs for youths. The number of
adolescents who received an antidepressant at
the index visit of a new episode of depression
grew from 5% at that point in 1998 to 37% in
2002 (Valuck et al. 2004).
With the advent of the FDA Modernization
Act (U.S. Congress 1997), which provided 6
months of additional market exclusivity for
pediatric studies, the number of industry-
sponsored MDD studies in children and adoles-
cents grew (Emslie et al. 2002; Wagner et al. 2003;
Wagner et al. 2004). Publications of industry-
conducted, double-blind, placebo-controlled
trials of fluoxetine, paroxetine, sertraline, and
citalopram reflected this expanding level of ac-
tivity. Following two positive randomized clin-
ical trials involving 315 youths 8–18 years of
age (Emslie et al. 2002; Emslie et al. 1997), the
FDA approved fluoxetine for the treatment of
pediatric MDD in January 2003. Fluoxetine re-
mains the only drug that is FDA-approved for
the treatment of depression in children and ado-
lescents. In fact, most of the pediatric trials in
depression have failed to discriminate between
active medication and placebo on primary effi-
cacy measure. Whereas this situation is not
substantially different from that in adult de-
pression, given the notoriously high rate of re-
sponse on placebo, it must be pointed out that
a particular feature of the FDA pediatric exclu-
sivity rule may contribute to it. In fact, the 6-
month additional exclusivity is granted for
merely conducting a pediatric trial and not
necessarily for showing efficacy.
Then, in mid-2003, the Medicine and Health
Care Products Regulatory Agency (MHRA) of
the British Department of Health issued a report
concluding that paroxetine was contraindicated
in patients with MDD under the age of 18. This
decision was based on an examination of pro-
prietary data, including both published and
unpublished data, that demonstrated a slight
increase in suicidal ideation and behavior (sui-
cidality) among patients randomized to parox-
etine as compared with those who received
placebo (3.7% versus 2.5%) and a lack of statis-
tically significant benefit.
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The MHRA notice proved to be the first in a
series of notices by both the FDA and MHRA
expressing concerns regarding antidepressants
in the treatment of pediatric depression. It also
marked the beginning of extensive analyses
conducted by both regulatory agencies and two
public hearings in 2004 regarding SSRIs and
suicidality, this time with a focus on the pedi-
atric population.
In December 2003, the MHRA completed a
summary analysis of their data regarding anti-
depressant use in pediatric depression. They
reported that there was no evidence of efficacy
for any SSRI in pediatric depression, except for
fluoxetine. Additionally, the MHRA described
a rate of adverse events that exceeded those of
placebo in many trials, with specific concerns
regarding suicidality. The MHRA concluded
that even if the risks were minimal, if there is
no evidence of benefit for the other antidepres-
sants, then the risk/benefit relationship for
these medications would be unacceptable.
In February 2004, the FDA convened a joint
meeting of their Psychopharmacologic Advi-
sory Committee and Pediatric Subcommittee
of the Anti-Infective Drugs Advisory Commit-
tee in order to evaluate the use of antidepres-
sants in children and adolescents. The goal of
this meeting was to review the safety and effi-
cacy data available through controlled trials of
antidepressants in children and adolescents.
The FDA was particularly concerned with ex-
amining the adverse events data regarding the
emergence or occurrence of suicide-related
events, including suicidal thinking as well as
actual self-harm. In the course of this review, it
became apparent that there were marked dif-
ferences in methods of data collection, coding,
and analyses of adverse event data across
studies. This necessitated a review and reclas-
sification of the suicidality adverse events in
order to accurately assess the available data. In
March 2004, as these analyses were being con-
ducted, the FDA issued a public health advi-
sory, as an interim step, asking manufacturers
of 10 different antidepressant drugs to include
in their label a warning section recommend-
ing close scrutiny for worsening depression
or emergence of suicidality in adult and pedi-
atric patients treated with these agents (FDA
2004a).
In September 2004, the results of a meta-
analysis of 24 controlled clinical trials of nine
antidepressants in approximately 4400 pedi-
atric patients were presented at a public hear-
ing. The 24 trials were conducted for various
indications, primarily MDD, but also for anxi-
ety and attention-deficit/hyperactivity disor-
der (ADHD). Although no completed suicides
occurred in these trials, the cumulative risk for
suicidality when adverse events were collected
by spontaneous report was approximately 4%
on active medication versus approximately 2%
on placebo, resulting in a relative risk of ap-
proximately 2 and a risk difference of 2%
(Hammad 2004). When data was systemati-
cally collected utilizing rating scales at base-
line and routinely throughout the trials, the
overall rates of treatment-emergent suicidality
and suicidal worsening were higher than was
reported using spontaneous adverse event re-
ports, but there was no difference between the
rates in the placebo and active drug groups
(Hammad 2004).
Based on the recommendations of the com-
mittee, the FDA took the following four actions
(FDA 2004b). They issued a “black box” warn-
ing that antidepressant use in children was ac-
companied by an increased risk for suicidality.
The warning was not limited to SSRIs, but in-
volved all antidepressants, and was not spe-
cific for depression, but included any use in
pediatric populations. Secondly, they required
a medication guide to accompany all prescrip-
tions. The medication guide included infor-
mation for parents regarding monitoring for
suicidality and adverse events with antidepres-
sants. Thirdly, they established guidelines for
frequency of monitoring when initiating anti-
depressants. Face-to-face follow-up with the
clinician weekly for 4 weeks, then every other
week for 4 weeks, and then monthly. And fi-
nally, they initiated unit-of-use packaging to
ensure that every patient receives the medica-
tion guide each time a prescription is filled.
The findings regarding suicidality have forced
clinicians to carefully consider the existing data
on: (1) The efficacy of antidepressants in this
population, (2) the potential harm of these
medications, and (3) what the implications are
for the treatment of children and adolescents
in their own practice.
SSRIs AND PEDIATRIC DEPRESSION 13
Efficacy data
In 2004, the FDA reviewed both published
and unpublished data on the efficacy of SSRIs
in pediatric depression and concluded that only
3 (two fluoxetine and one citalopram) of 15 pe-
diatric MDD trials showed evidence of efficacy,
defined as a statistically significant (p < 0.05)
superiority of active medication over placebo
on the primary outcome measure (Table 1).
(Note: The results of TADS were not yet avail-
able at the time this summary was prepared.)
Three other trials (Keller et al. 2001; Wagner et
al. 2003) were believed to provide some sug-
gestion of potential benefit, but they did not
meet FDA guidelines for a “positive” efficacy
study. The trial of paroxetine (Keller et al. 2001)
was positive on several secondary endpoints,
though not on the primary outcome, while the
two trials of sertraline showed a positive pri-
mary endpoint only when their data were
pooled and analyzed (Wagner et al. 2003).
These data provide support for the FDA in-
dication of fluoxetine for pediatric depression.
The summary of these data also highlight the
fact that the majority of studies conducted to
date on pediatric depression were unpublished
and that all of the unpublished studies were
negative studies (i.e., did not demonstrate a ben-
efit of active medication compared to placebo
on the primary outcome measure).
Published versus unpublished data. Clinicians
and the general public receive their informa-
tion on clinical trials through published data.
A meta-analysis assessed conclusions based on
published data and contrasted those to con-
clusions reached by combining published and
unpublished data (Whittington et al. 2004).
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TABLE 1. PRIMARY OUTCOME RESULTS FOR ACUTE (8–12 WEEK) PLACEBO-CONTROLLED PEDIATRIC STUDIES OF
SSRIS AND RELATED SEROTONERGIC DRUGS IN MAJOR DEPRESSION
Primary outcome Age
continuous range Outcome* (drug
Drug Publication N measurec (years) versus placebo)
Paroxetine Keller et al. 2001 275 HAM-D 12–18 Negativea
Paroxetine Berard et al. 2006 275d MADRS 13–18 Negative
Paroxetine Emslie et al. in press 203e CDRS-R 7–17 Negative
Fluoxetine Emslie et al. 2002 219 CDRS-R 8–18 Positive
Fluoxetine Emslie et al. 1997 96 CDRS-R 8–17 Positive
Fluoxetine TADS 2004 439 CDRS-R 12–17 Positive
Sertraline Wagner et al. 2003 160 CDRS-R 6–17 Trend
Sertraline Wagner et al. 2003 160 CDRS-R 6–17 Negativeb
Venlafaxine Unpublished 161 CDRS-R 7–17 Negative
Venlafaxine Unpublished 193 CDRS-R 7–17 Negative
Citalopram Wagner et al. 2004 174 CDRS-R 7–17 Positive
Citalopram Unpublished 244 CDRS-R 13–18 Negative
Nefazodone Unpublished 195 CDRS-R 12–18 Trend
Nefazodone Unpublished 273 CDRS-R 7–17 Negative
Mirtazapine Unpublished 126 CDRS-R 7–17 Negative
Mirtazapine Unpublished 124 CDRS-R 7–17 Negative
Source: Adapted from Laughren TP. Memorandum, January 5, 2004: Background comments for February 2, 2004
Meeting of Psychopharmacological Drugs Advisory Committee (PDAC) and Pediatric Subcommittee of the Anti-
Infective Drugs Advisory Committee (AC), Bethesda, MD.
*Positive (p # 0.05); negative (p $ 0.10); Trend (0.05 < p # 0.10) on primary efficacy outcome.
aKeller et al. 2001; positive on most secondary endpoints.
bWagner et al. 2003; positive on pooling of two studies.
cMany studies also included responder rate as a primary categorical outcome in addition to the continuous rating
of depressive symptoms.
SSRIs = selective serotonin reuptake inhibitors; HAM-D = Hamilton Depression Rating Scale; MADRS=
Montgomery-Åsberg Depression Rating Scale; CDRS-R = Childhood Depression Rating Scale—Revised.
d286 randomized, but only 275 analyzed.
e206 randomized, but only 203 analyzed.
Five published, acute, randomized, placebo-
controlled trials of SSRIs in pediatric depres-
sion were compared with all unpublished data
included in the United Kingdom’s Committee
on Safety of Medicines’ review. All of the flu-
oxetine trials had been published, and two trials
(Emslie et al. 2002; Emslie et al. 1997) sup-
ported its efficacy in pediatric major depression,
suggesting a favorable risk/benefit profile. The
published results of one paroxetine trial and
two sertraline trials suggested equivocal or
weakly positive efficacy which, in the case of
paroxetine, was not supported by two other
then-unpublished trials (Berard et al. 2006).
Likewise, efficacy of citalopram was supported
by one published trial (Wagner et al. 2004) but
not by an unpublished one (Table 1). For ven-
lafaxine and mirtazapine, two unpublished trials
for each compound did not demonstrate effi-
cacy. In the face of unproven efficacy and the
potential for suicidality as an adverse event,
the authors concluded that the risk/benefit pro-
files for paroxetine, sertraline, venlafaxine, and
mirtazipine were unfavorable (Whittington et
al. 2004; Whittington et al. 2005).
The discrepancies between published and
unpublished data highlight the potential for
biased reporting of positive versus negative
results. Whittington et al. (2005) expressed
concerns that clinical guideline development
and clinical decisions regarding treatment are
largely dependent on the evidence base estab-
lished through peer-reviewed journals and
that nonpublication of trials could lead to erro-
neous recommendations for treatment.
TADS data. The Treatment for Adolescents
with Depression Study (TADS) is an NIMH-
sponsored multisite trial comparing fluoxetine,
cognitive behavioral therapy (CBT), their com-
bination, and placebo in 439 adolescents with
a primary diagnosis of major depression (TADS
Team 2004). The acute-phase TADS results were
not available at the time of the initial FDA ad-
visory committee meeting in February 2004,
but they were published and available by the
time the committee reconvened in September
of that year. TADS is significant in that it was
the largest acute treatment study of depression
in youths. Additionally, TADS had a psychoso-
cial treatment arm, both stand alone and in
combination with fluoxetine, which had not
been included in previous antidepressant trials.
TADS had two primary outcome measures,
the scalar Children’s Depression Rating Scale—
Revised (CDRS-R; Poznanski and Hartmut 1996)
total score and the end-of-treatment response
rate defined by a categorical Clinical Global
Impression—Improvement score (CGI-I) of
much or very much improved. CDRS-R adjusted
mean (standard deviation) scores at baseline,
week 6, and week 12 were: CBT with fluoxe-
tine 60.79 (4.85), 38.10 (7.78), 33.79 (8.24); flu-
oxetine alone 58.94 (4.00), 39.80 (7.37), 36.30
(8.18); CBT alone 59.64 (4.52), 44.63 (8.30),
42.06 (9.18); placebo 61.18 (4.27), 44.90 (7.32),
41.77 (7.99). Pairwise contrasts on the CDRS-R
regression slope coefficients showed that com-
bination treatment with fluoxetine and CBT was
statistically superior to placebo (p = 0.001),
CBT (p = 0.001), and fluoxetine (p = 0.02),
whereas fluoxetine alone was statistically supe-
rior to CBT (p = 0.01) but not placebo (p = 0.10).
Supporting analyses performed on the week
12 CDRS-R adjusted means demonstrated flu-
oxetine with CBT (p = 0.001) and fluoxetine
alone (p = 0.002) to be superior to placebo,
whereas CBT alone was not (p = 0.97). Fluoxe-
tine with CBT was superior to CBT alone (p =
0.001) but not to fluoxetine alone (p = 0.13),
whereas fluoxetine alone was superior to CBT
alone (p = 0.001). The other primary efficacy
outcome measure, the CGI-I-defined rates of
response, showed that more patients were re-
sponders to combination therapy (71%) or flu-
oxetine (61%) than to CBT (43%) or placebo
(35%; p # 0.01) (TADS Team 2004).
Thus, on one of the two primary analyses,
fluoxetine approached statistical significance
compared to placebo, although it was signifi-
cantly better than CBT. However, the prepon-
derance of the evidence from the other positive
primary analysis and supporting analyses,
using end-of-treatment CDRS-R scores, sup-
ports, the use of fluoxetine alone in decreasing
depressive symptoms.
The clinical impact of treatment on outcome
was evaluated by calculating the effect size
and the number needed to treat (NNT) to each
additional responder, based on the adjusted
means. The effect size derived from the CDRS-
R was 0.98 for fluoxetine with CBT, 0.68 for
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fluoxetine alone, and 20.03 for CBT alone. Ef-
fect sizes from the odds ratio (OR) for the di-
chotomized CGI-I were 0.84 for fluoxetine with
CBT, 0.58 for fluoxetine alone, and 0.20 for CBT
alone. The NNT for the dichotomized CGI-I for
fluoxetine and CBT was 3 (95% Confidence In-
terval [CI], 2–4), for fluoxetine alone was 4
(95% CI, 3–8), and for CBT alone 12 (95% CI,
5–23). Thus, the largest study to date of ado-
lescent depression provided clear evidence of
fluoxetine’s efficacy in adolescents with mod-
erate to severe depression.
Summary. Based upon these clinical trials, flu-
oxetine does appear to have efficacy in the treat-
ment of pediatric depression, with the majority
of the trials demonstrating positive results.
These data, combined with the TADS data sug-
gesting that psychotherapy alone faired poorly
compared to fluoxetine and that the best treat-
ment combination has fluoxetine as a com-
ponent, would lend support to the use of
fluoxetine in the treatment of pediatric MDD.
Support for efficacy also exists for sertraline,
citalopram, and paroxetine. However, the effi-
cacy signal for these drugs is weaker and incon-
sistent, as shown by the inability to replicate it in
other studies. It is entirely possible that this vari-
ability in outcome is similar to what is seen in
the adult literature, where antidepressants ap-
proved by the FDA for the treatment of adult
MDD frequently have as many negative as posi-
tive trials. Finally, no efficacy signal has
emerged for venlafaxine or mirtazapine.
Whether the discrepancy between the fluoxetine
and other SSRI’s data is better explained by ex-
perimental error owing to methodological fac-
tors in study design and conduct (more likely, as
evidenced by the variability in placebo re-
sponse) or by substantive pharmacological dif-
ferences (less likely) remains a matter of debate.
Safety data
Risk of treatment. In September 2004, when the
FDA presented results of their meta-analysis
of 25 trials plus TADS, safety data were pre-
sented in addition to the efficacy data (Ham-
mad 2004). In order to make the clinical trial
datasets more uniform with respect to adverse
event reporting, an independent team of ex-
perts utilized a novel approach developed by
researchers at Columbia University to evalu-
ate and recode all adverse events for suicidal
and self-injurious behaviors (suicide attempt,
preparatory acts, suicidal ideation, and so
forth). Following reclassification, 78 of the ap-
proximately 4400 subjects from these datasets
(1.7%) were coded as experiencing either suici-
dal behavior (n = 33) or suicidal ideation (n =
45). Once a uniform classification was applied,
relative risks for suicidal ideation and behav-
ior were calculated by drug and by study indi-
cation (Table 2). There were no completed
suicides, and only venlafaxine and fluoxetine
in TADS exhibited a statistically significant sig-
nal for suicidality (suicide attempts or suicidal
ideation). The overall relative risk (RR) for sui-
cidality was 1.66 (95% CI; 1.02, 2.68) for MDD
trials and 1.95 (1.28, 2.98) for all trials, all indi-
cations. The authors of the analysis concluded
that: “Although the difference is small, it seems
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TABLE 2. OVERALL RELATIVE RISKS OF SUICIDAL BEHAVIOR OR IDEATION BY DRUGS IN MDD TRIALS AS DEFINED BY THE
COLUMBIA UNIVERSITY RECLASSIFICATION PROJECT (HAMMAD 2004)
Drug Relative risk (95% CI), MDD trials Relative risk (95% CI), all trials, all indications
Citalopram 1.37 (0.53, 3.50) 1.37 (0.53, 3.50)
Fluvoxamine No MDD trials 5.52 (0.27, 112.55)
Paroxetine 2.15 (0.71, 6.52) 2.65 (1.00, 7.02)
Fluoxetine (including TADS) 1.53 (0.74, 3.16) 1.52 (0.75, 3.09)
Sertraline 2.16 (0.48, 9.62) 1.48 (0.42, 5.24)
Venlafaxine 8.84 (1.12, 69.51) 4.97 (1.09, 22.72)
Mirtazapine 1.58 (0.06, 38.37) 1.58 (0.06, 38.37)
Nefazodone No events No events
Bupropion No MDD trials No events
MDD = major depressive disorder; CI = Confidence Interval.
likely that the effect is real, because the find-
ings were statistically significant in aggregate
and are consistent across multiple studies of
various agents” (Brent 2004).
This issue can be analyzed in terms of “risk
difference,” which provides an estimate of the
absolute increase in risk of the event of interest
attributable to treatment, in this case, suicidal-
ity. This is calculated by subtracting the risk in
the placebo group from the risk in the active
drug group. The overall risk difference for the
SSRIs in the MDD trials is approximately 2%.
In other words, 2 patients of 100 treated with
an SSRI for major depression would be expected
to have an increase in suicidality during short-
term treatment attributable to the drug. Suici-
dality, when it did occur, was primarily ideation,
with only a minority of events involving ac-
tual suicide attempts (27 suicide attempts, 6
“preparatory actions),” and 45 suicidal ideation
events). Additional risk beyond that is inher-
ent in the disorder being treated (Hammad 2004).
In addition to an increase in the risk of sui-
cidality, SSRIs are almost twice as likely as
placebo to cause increased agitation and hos-
tility during acute treatment (Table 3). At this
time, it is unclear whether the increased risk
for suicidality associated with these medica-
tions is mediated by the agitation and hostility
symptoms, but it is important for patients and
families to be aware of this potential.
FDA conclusions regarding risk. The advisory
committee to the FDA concluded that the ad-
verse events reported voluntarily during clini-
cal trials in aggregate did indicate an increased
risk of treatment-emergent suicidality. Although
there was variability in the adverse event data,
the committee was unable to conclude that
any single antidepressant was free of risk. The
committee suggested additional research is
needed to further delineate the risks and bene-
fits of these drugs in pediatric patients with
psychiatric illness. Additional efficacy data and
more safety data focusing specifically on sui-
cidality are needed. Long-term trials using
placebo and fluoxetine as controls, as well as
additional NIH projects aimed at improving
our understanding of the natural and longitu-
dinal course of depression and suicidality,
would better inform clinicians how to diagnose
and treat pediatric depression.  The risks asso-
ciated with pharmacological and nonpharma-
cological interventions, as well as the risks of
not treating depressed children and adoles-
cents, should also be assessed (FDA 2004b).
Since the FDA’s October 2004 “black box”
warning and additional recommendations re-
garding antidepressant use in children, other
regulatory bodies have also released warn-
ings. In April 2005, the European Medicines
Agency issued a press release regarding their
review of SSRI and SNRI medicines in children
and adolescents (atomoxetine, citalopram, du-
loxetine, escitalopram, fluoxetine, fluvoxamine,
mianserine, milnacipran, mirtazapine, paroxe-
tine, reboxetine, sertraline and venlafaxine).
They recommended: “. . . strong warnings
across the whole of the European Union to
doctors and parents about these risks. Doctors
and parents will also be advised that these
products should not be used in children and
adolescents except for their approved indica-
tions.”  Approved indications in the pediatric
population are limited to obsessive-compulsive
disorder (OCD) for a few of the agents and
ADHD for atomoxetine (European Medicines
Agency 2005).
TADS data pertaining to risk. TADS provided a
systematic approach to collecting data on sui-
cidality, beginning at baseline and continuing
to all subsequent endpoints, which allows for
a longer-term assessment of the role of various
treatments on suicide. At baseline, clinically
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TABLE 3. OVERALL RELATIVE RISK OF TREATMENT-
EMERGENT AGITATION OR HOSTILITY BY DRUG IN
MDD TRIALS (HAMMAD 2004)
Drug Relative risk (95% CI), MDD trials
Citalopram 1.87 (0.34, 10.13)
Paroxetine 7.69 (1.80, 32.99)
Fluoxetine (does not include 1.01 (0.40, 2.55)
TADS)
Sertraline 2.92 (0.31, 27.83)
Venlafaxine extended-release 2.86 (0.78, 10.44)
Mirtazapine 0.52 (0.03, 8.27)
Nefazodone 1.09 (0.53, 2.25)
All drugs 1.79 (1.16, 2.76)
MDD = major depressive disorder; CI = Confidence
Interval.
significant suicidal thinking was present in 29%
of the sample, as measured by the CDRS-R
suicide item and the Suicidal Ideation Ques-
tionnaire–Junior High School Version (SIQ-Jr;
Reynolds 1987). Suicidality declined signifi-
cantly in all four treatment groups with fluox-
etine plus CBT showing the greatest reduction
(p = 0.02). There were no completed suicides in
the course of the study, but 24 (5.5%) of the 439
TADS patients experienced a suicide-related
event. Seven (7) of the 24 suicide-related events
were suicide attempts (1.6% of the total sam-
ple). Four (4) of the attempts were by patients
assigned to fluoxetine and CBT, 2 to fluoxetine
alone, and 1 to CBT alone. None of the subjects
taking placebo attempted suicide.
Harm-related events, which included thoughts
or behaviors related to harm of self as well as
harm to others, occurred in 11.9% of those as-
signed to fluoxetine alone, 8.4% fluoxetine with
CBT, 4.5% CBT alone, and 5.4% placebo.
Overall, suicidality decreased with treatment.
Improvement was greatest for those receiving
combination treatment and least for those re-
ceiving fluoxetine alone. It is important to note
that, though fluoxetine did not appear to in-
crease suicidal ideation, the harm-related ad-
verse events did occur more frequently in
fluoxetine-treated patients (TADS Team 2004).
Epidemiological and observational data. Although
no causality can be determined, nonexperimen-
tal studies using community or observational
data offer a perspective complementary to the
information from controlled clinical trials of
antidepressant use in children and adolescents.
Whereas the pediatric use of antidepres-
sants has substantially increased throughout
the previous decade, the overall youth sui-
cide rates had been declining (Olfson et al.
2003). During 1992–2001, for example, the
overall suicide rate among persons 10–19
years of age declined from 6.2 to 4.6 per
100,000 population (CDC 2004). A significant
inverse relationship was also found between
regional rates of antidepressant medication
use and suicide rates of 10- to 19-year-old
youths in the United States in 1990–2000.
Each 1% increase in antidepressant use was
associated with a decrease of 0.23 suicides per
100,000 adolescents per year.
Valuck et al. assessed antidepressant use in
youth by analyzing a large database of insur-
ance claims from both commercial and Medic-
aid plans. They examined claims filed (January
1997 to March 2003) from various regions across
the United States on adolescents newly diag-
nosed with MDD who had at least 6 months of
follow-up data (Valuck et al. 2004). The data-
base of 24,119 adolescents revealed crude sui-
cide attempt rates, ranging from 0.0% to 2.3%.
Treatment with SSRIs (hazard ratio [HR] = 1.59;
CI, 0.70, 2.89), other antidepressants (HR =
1.03; CI, 0.43, 2.44), or multiple antidepressants
(HR = 1.43; CI, 0.70, 2.89) after index MDD di-
agnosis resulted in no statistically significant
increase in risk of suicide attempt. Thus, whereas
the SSRIs were associated with a numerically
higher risk of suicide attempt (HR 1.59), the in-
crease failed to reach statistical significance.
Treatment with an antidepressant medication
for at least 180 days reduced the likelihood of a
suicide attempt, as compared to treatment
courses of less than 55 days (HR = 0.34; CI,
0.21, 0.55). The authors concluded that antide-
pressants had no statistically significant effects
on the likelihood of suicide attempts.
A review of National Vital Statistics from the
Centers for Disease Control and Prevention ana-
lyzed records of all U.S. individuals at the county
level who committed suicide between 1996 and
1998, examining the association between antide-
pressant prescription and suicide rate (Gibbons
et al. 2005). Change in prescription rates of tri-
cyclic antidepressants (TCAs), SSRIs, and other
non-SSRI antidepressants from 1996 to 1998
were obtained for each county. The data demon-
strated lower suicide rates in association with in-
creased use of selective serotonin reuptake
inhibitors and new-generation non-SSRIs, com-
pared to TCA use. Suicide rates tended to be
higher in counties with larger proportions of
TCA prescriptions. As the authors point out, this
type of data cannot demonstrate causal relation-
ships because the higher number of TCA pre-
scriptions may simply be a marker for counties
with more limited access to mental health care.
The higher rates of suicides with TCA prescrip-
tions may also reflect the greater toxicity in over-
dose of TCAs. After adjusting for age, gender,
race, income, and county-to-county variability in
suicide rates, the overall relationship between all
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prescribed antidepressants and suicide rate was
not statistically significant (p = 0.14).
Jick et al. conducted an evaluation of antide-
pressant prescriptions utilizing a matched case-
control design based on patients’ prescriptions/
diagnoses in the U.K. General Practice Research
Database (GPRD), 1993–1999 (Jick et al. 2004).
Data were collected on patients 10–69 years of
age treated with amitriptyline, fluoxetine, parox-
etine, and dothiepin (reference group), assess-
ing cases of nonfatal suicide behavior (ideation
or attempts) (n = 555), suicides (n = 17), and
controls (n = 2062) without suicidal behavior.
Compared to dothiepin, there was no statisti-
cally significant difference in suicidality with
one antidepressant compared to another, with
a range for the relative risk (RR) for nonfatal
suicide behavior of 0.83–1.29. Results were sim-
ilar for patients 10–19 years of age, although
the sample of adolescent cases was small. There
were no suicides in the 10–19 year olds pre-
scribed medication in this study population.
However, in reviewing the entire GPRD popu-
lation from 1993 to 1999, 15 persons in this age
group had committed suicide, none of whom
had received an antidepressant drug.
Jick et al.’s evaluation of the time-course of
suicidal events is also of clinical interest. The
RR of nonfatal suicidal behavior/suicide was
highest for patients within 1–9 days of the an-
tidepressant being prescribed (versus 90 days
or more). The RR for nonfatal suicidal behav-
ior during this earlier time period was 4.07
(95% CI, 2.89–5.74), whereas the RR for suicide
was 38.0 (95% CI, 6.2–231). Although this could
indicate an exacerbation of suicidality during
the initiation of treatment, it could also be re-
lated to the acuity that prompted the initiation
of the treatment. It has been reported, even
prior to the antidepressant era, that people were
most likely to commit suicide as they were
coming out of a depressive episode.
Also, though it has been hypothesized that
abrupt discontinuation of antidepressants may
play a role in exacerbation of symptoms and
suicidality, there was no statistically significant
association between discontinuation of an an-
tidepressant and nonfatal suicidal behavior.
Another way to determine whether SSRIs
are implicated in completed suicides is through
toxicological analysis of individuals dying from
suicide. A study of suicide in more than 5000
adults found that, most often, antidepressants
had not been taken immediately before death,
even though the majority of the persons had
been depressed (Isacsson et al. 1997). A study
of 14,857 suicides and 26,422 other deaths in
Sweden (Isacsson et al. 2005) found that none
of the 15 suicides below the age of 15 years had
an SSRI detected on toxicology. In 15–19-year-
old suicide victims, SSRIs had a lower relative
risk in suicides compared with non-SSRIs. These
findings do not support the suggestion that
SSRIs are triggering suicides in adults or youth.
In a study of 49 adolescent suicides in Utah,
24% had been prescribed antidepressants, but
none had tested positive for SSRIs at the time
of death (Gray et al. 2003). In a postmortem
study conducted on 66 suicides among per-
sons under 18 years of age in New York City
from 1993 through 1998 (Leon et al. 2004), 54
(81.8%) had serum toxicological analysis for
antidepressants and an injury-death interval
of 3 days or less. Imipramine was detected in 2
victims and fluoxetine in another 2 (total 10%).
None of the other 90% of suicides had antide-
pressants detected. Most postmortem studies
in adults have found that over 80% of depressed
patients at the time of suicide are not on anti-
depressants.
Risk of nontreatment. When weighing the po-
tential risks and benefits of treatment, it is also
important to consider the risk of not treating
MDD. Suicide is the third-leading cause of
death among adolescents 15–19 years of age,
and fourth-leading cause of death among 10-
to 14 year olds (Anderson 2002). The depressed
pediatric subjects followed by Fombonne et al.
into adulthood demonstrated a suicide risk of
2.45%, with 44.3% of the sample attempting sui-
cide once in their lives (Fombonne et al. 2001).
Weissman et al. also found an elevated risk
of suicide and comorbidity in long-term fol-
low-up studies of depression. During a period
spanning approximately 10 years between ado-
lescence and early adulthood, they estimated a
5-fold increased likelihood of suicide attempt
associated with pediatric depression (Weissman
et al. 1999a; Weissman et al. 1999b). Prepuber-
tal children with an earlier age of MDD onset
are also at increased risk for substance abuse,
SSRIs AND PEDIATRIC DEPRESSION 19
conduct disorder, overall impaired function-
ing, and need for long-term psychiatric and
medical services (Weissman et al. 1999b). Clin-
ical outcomes in adulthood of adolescent onset
MDD demonstrated a high rate of suicide (7.7%)
and a 5-fold increase for a first suicide attempt
(Weissman et al. 1999a).
Unfortunately, the available treatment inter-
ventions have limited data on acute efficacy
and unproven effectiveness in improving the
long-term outcome of the disorder. Nonethe-
less, fluoxetine remains the most effective acute
intervention, either alone or in combination
with psychotherapy, for decreasing depressive
symptoms in adolescents suffering from mod-
erate to severe depression. However, special-
ized psychotherapy alone does not seem to be
a valid therapeutic option for these moder-
ately to severely depressed patients (TADS
Team 2004).
Summary. Analyses of suicidality adverse
events collected in the pediatric antidepres-
sant trials have demonstrated an elevation in
suicidality when placebo was compared to
active medication. Systematic and repeated
assessments of suicidality using symptom
rating scales, however, have not supported
this finding. In fact, when these data were
collected in TADS at baseline, 6 weeks, and
12 weeks, all four treatment groups demon-
strated a decline in suicidality, with the
greatest decline occurring in the group re-
ceiving fluoxetine with CBT.  Also of interest
are the epidemiological and observational
data, which demonstrate an increase in the
use of SSRIs in the pediatric population but
no corresponding increase in completed sui-
cides. In fact, studies have generally identi-
fied an inverse correlation, both nationally
and regionally, with suicide and antidepres-
sant usage.
DISCUSSION
The pharmacological treatment of pediatric
depression has recently undergone intensive
scrutiny and discussion. Throughout the pro-
cess, a better understanding of the potential
risks and benefits has evolved. There is a clear
need for additional clinical trials to systemati-
cally assess these issues, but this will obvi-
ously be an extended process. At this point,
the task for the clinician is to be aware of what
information is available and to make an in-
formed decision regarding the balance between
potential benefits and risks when deciding upon
a treatment plan for the individual patient.
Various statistical methods can be employed
to assess benefit versus risk (Whittington et al.
2004). However, interpretation of these data
must ultimately be conducted in a clinical con-
text. The decision as to whether the calculated
risk is favorable, for example, to induce one
adverse event for every 10 patients showing
improvement, is dependent on the severity of
the event and the presence of better alternatives.
It is possible that, at times, the ease of use,
tolerability, and perceived efficacy of the SSRIs
in clinical practice led to an overly casual pat-
tern of usage in treating pediatric disorders.
Despite increasing rates of antidepressant usage,
it is difficult to argue that these medications
are overprescribed, as the ratio of prescrip-
tions for the treatment of depression to preva-
lence of MDD remains much less than one.
Considerable evidence supports the use of
fluoxetine for pediatric MDD. However, even
fluoxetine carries risks, which must be consid-
ered in the risk/benefit analysis and treatment
planning. The TADS Team concluded that:
“The combination of fluoxetine with CBT of-
fered the most favorable tradeoff between ben-
efit and risk for adolescents with major
depressive disorder” (TADS Team 2004). Com-
bination therapy may be the best treatment for
teenagers with major depression, especially
when the depression is moderate to severe and
there is a history of past or present suicidality.
Whereas CBT alone was not better than
placebo, and, by most measures, was inferior
to combination treatment or fluoxetine alone,
it proved to be a useful adjunct to pharmaco-
therapy. CBT also demonstrated usefulness,
both alone and in combination with fluoxetine,
in the reduction of suicidal thoughts and be-
haviors. Because nearly 40% of depressed
teens do not respond to fluoxetine and others
aren’t able to tolerate it, treatments other than
fluoxetine should continue to be studied and
be made available.
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What we still do not know
Despite a recent expansion of data, our
knowledge base about the efficacy and safety
of SSRIs remains limited, with many unan-
swered questions:
• Are there clinically significant differences
between prepubertal and adolescent de-
pression with respect to antidepressant
treatment efficacy and safety? If so, what
are the underlying causes of such differ-
ences?
• Are there clinically significant differences
among SSRIs and similarly related antide-
pressants with respect to efficacy and/or
safety?
• What accounts for the apparent discrep-
ancy between the efficacy of SSRIs in adult
depression and the much weaker and in-
consistent data in the pediatric population?
Is pediatric depression a substantively dif-
ferent condition than depression in adults?
There is a need to better understand the
longitudinal course of child and adoles-
cent depression and its relationship to adult
major depression. Are the assessment
methods used in pediatric clinical trials
not sufficiently sensitive and specific for
measuring depression? Because there have
been a significant number of adult studies
but very few pediatric studies, is the lack
of positive pediatric studies simply a man-
ifestation of fewer studies conducted?
• How can one best interpret “negative” trials
of antidepressants? It is important to note
that negative studies do not necessarily
prove a lack of efficacy. The placebo re-
sponse in depression trials can be signifi-
cant, owing, in part, to study design and
can potentially lead to an inability to dem-
onstrate efficacy, even for a robust treat-
ment. But negative trials cannot be fully
dismissed either, especially when they are
properly designed and statistically pow-
ered to reject the null hypothesis.
• Likewise, are there real differences in
safety of SSRIs between children/adoles-
cents and adults? Why is an association
between SSRIs and suicidality detectable
in pediatric data, but not in the much
larger database of adult studies (Martinez
et al. 2005)? Will closer examination of
adult data reveal that youth are not specif-
ically at risk and the risk regarding suici-
dality is ubiquitous across developmental
stages? 
• Which subgroup of depressed youths are
the best candidates for antidepressant treat-
ment and which ones are likely to respond
to nonpharmacological interventions?
• Randomized clinical trials rely on “suici-
dality” measures, such as suicidal ideation
and suicidal attempts. But what is the re-
lationship between suicidality and com-
pleted suicide? Can increased risk for
suicidality be considered a valid marker
for increased risk for suicide? Epidemio-
logically, the relationship among suicidal
ideation, suicidal attempts, and suicide is
not linear, as suicide has decreased in the
last 10 years, but rates of suicidal ideation
and suicidal attempts have not (Kessler et
al. 2005).
• What is the most effective way to monitor
patients for safety during treatment with
antidepressants? The FDA has issued spe-
cific recommendations that the clinician
should see children and adolescents on a
weekly basis during the 1st month of treat-
ment. This recommendation is based on
usual practice in clinical trials, but no em-
pirical evidence currently supports this
schedule of visits over less intensive but
potentially equally effective approaches
(e.g., biweekly visits, with weekly phone
contacts between visits).
• We know from controlled studies that there
can be an increased risk of self-harm and
aggression in the short term, but we do
not know if the risk disappears or addi-
tional benefits emerge beyond 2–3 months
of treatment.
• How can a clinician distinguish suicidality
that is causally related to the treatment
delivered from suicidality that emerges as
a result of the underlying illness? Stop-
ping antidepressant treatment with the
emergence of worsening suicidality may
become the norm with the current warn-
ings. However, recent FDA analyses indi-
cate that only 50% of emerging suicidality
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is related to prescribed treatment and 50%
to other causes, with no way for the clini-
cian to distinguish between the two. This
could lead to premature discontinuation
of an effective treatment. Additionally, what
should a clinician do after a treatment is
discontinued for suicidality? Does one
make a determination that a child is “al-
lergic” to SSRIs and try nondrug strategies,
or challenge with a second SSRI, or pre-
scribe alternatively untested medication
or psychotherapy?
The recent concerns about SSRIs have illus-
trated the value of having conducted 15 ran-
domized clinical trials in pediatric depression
in a relatively short period of time. Without
data from these trials, no assessment of benefit
and risk could have been even attempted. How-
ever, studies with small sample sizes, such as
those conducted to date, will never answer im-
portant safety questions where the outcomes
of interest occur infrequently. It is not practical
to design a randomized clinical trial with sui-
cide as an endpoint, owing to the sample size
and duration of a study necessary to evaluate
the risk of such an uncommon event. More-
over, establishing relative risk by drug, drug
class, subgrouping (e.g., age, gender, disorder)
and understanding some aspect of mechanism
(e.g., activation) requires very large samples.
Hence, practical clinical trials (March et al. 2004;
March et al. 2005) are essential if we are to
learn more about predictors and management
of risk. It is extraordinary that no one has risen
to this challenge, to address this significant
public health issue, and advocates for de-
pressed youths shouldn’t avoid saying so.
CONCLUSIONS
Essentially, the present use of SSRIs in the
treatment of pediatric depression is an in-
formed consent issue. The clinician must openly
discuss the risks and benefits of the various
treatment options with the youth and parents
prior to the selection of the most appropriate
treatment for that specific child. With the in-
crease in clinical trials and epidemiological
databases, clinicians can more accurately dis-
cuss the risk/benefit relationships. However,
much remains to be discovered and learned
about the treatment of pediatric depression.
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